Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterward considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests.
Its findings support relapse recovery as a critical factor for DMT initiation, and one that should be assessed routinely in MS clinical trials, researchers said.
The study, “Relapse recovery: The forgotten variable in multiple sclerosis clinical trials,” was published in the journal Neurology: Neuroimmunology & Neuroinflammation.
How well a person recovers from an MS relapse is known to affect long-term disease course, with partial recovery being associated with residual disability and earlier onset of progressive MS.
While the effectiveness of DMTs — treatments that reduce the activity and progression of a disease — is known to lessen over time with MS, the role of early relapse recovery in their effectiveness remains unclear.
“A common real-world practice in deciding immediate vs delayed DMT initiation in early MS often involves the extent and rapidity of a patient’s recovery from early relapses, a decision for which there is no evidence from a clinical trial setting,” the researchers wrote.
A team with the Mayo Clinic College of Medicine and Science in Minnesota and Biogen set out to clarify how the degree of recovery from an early relapse impacts the effectiveness of Biogen’s Avonex (interferon beta-1a), a DMT, in halting disease progression, and whether such recovery should define the moment of DMT initiation.
Researchers analyzed data from the Phase 3 CHAMPS clinical trial testing Avonex in a group of people with clinically isolated syndrome (CIS) — which often precedes MS development — and its follow-up extension study called CHAMPIONS (NCT00179478).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?